<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122431</url>
  </required_header>
  <id_info>
    <org_study_id>HPLC-Rheumatic diseases</org_study_id>
    <nct_id>NCT03122431</nct_id>
  </id_info>
  <brief_title>Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases</brief_title>
  <official_title>Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      No drug treatment is completely free of risk and lack of response, adverse events and poor
      adherence may affect its effectiveness. Within this context, this project aims to evaluate
      the importance of monitoring blood levels and salivary drug used in rheumatic autoimmune
      diseases in the monitoring of adherence to therapy. In addition, this project intends to use
      the monitoring of drug levels, based on pharmacokinetic studies and
      pharmacokinetics/pharmacodynamics modeling, to broaden the understanding of the possible
      cellular, tissue and immunological mechanisms involved in efficacy and adverse effects of
      these drugs with the prospect of reducing the damage and maintain therapeutic efficacy. The
      high-performance liquid chromatography (HPLC) coupled to mass spectrometry, which will be
      used to evaluate hydroxychloroquine, thalidomide, glucocorticoids, is considered the gold
      standard technology to qualitative and quantitative analysis of drugs in blood and its
      comparison with the dosage in the saliva is an improvement in simplification of the process.
      For biological agents the focus will be on the understanding the loss of efficacy and the
      possible role of anti-TNF antibodies using ELISA capture methodology.This project will be
      divided into four sections with their respective sub-projects according to the medications
      that will be studied: hydroxychloroquine, thalidomide, biologic agents and glucocorticoids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No drug treatment is completely free of risk and lack of response, adverse events and poor
      adherence may affect its effectiveness. There is also a large inter-individual variability in
      response to treatments with regard to efficacy and toxicity, and for many drugs, there is
      also a period of weeks to months to establish its efficacy. Within this context, this project
      aims to evaluate the importance of monitoring blood levels and salivary drug used in
      rheumatic autoimmune diseases in the monitoring of adherence to therapy. In addition, this
      project intends to use the monitoring of drug levels, based on pharmacokinetic studies and
      pharmacokinetics/pharmacodynamics modeling, to broaden the understanding of the possible
      cellular, tissue and immunological mechanisms involved in efficacy and adverse effects of
      these drugs with the prospect of reducing the damage and maintain therapeutic efficacy. The
      high-performance liquid chromatography (HPLC) coupled to mass spectrometry, which will be
      used to evaluate hydroxychloroquine, thalidomide, glucocorticoids, is considered the gold
      standard technology to qualitative and quantitative analysis of drugs in blood and its
      comparison with the dosage in the saliva is an improvement in simplification of the process.
      The implementation of this methodology dedicated to research in our center, with the
      necessary training of human resources, will enable the standardization and availability of
      this advanced technology to other muldisciplinary projects in various areas of science. For
      biological agents the focus will be on the understanding the loss of efficacy and the
      possible role of anti-TNF antibodies using ELISA capture methodology.This thematic project
      will be divided into four sections with their respective sub-projects according to the
      medications that will be studied: hydroxychloroquine, thalidomide, biologic agents and
      glucocorticoids.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2017</start_date>
  <completion_date type="Anticipated">June 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study includes 3 subprojects that will assess serum drug levels for efficacy and toxicity. In the first two subprojects, hydroxychloroquine will be studied in SLE population. In the third subproject, thalidomide and SLE and cutaneous lupus will be studied.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum levels of thalidomide</measure>
    <time_frame>30 days, 3 months, 6 months and 12 months</time_frame>
    <description>Improvement of Cutaneous Lupus Area and Severity Activity Index Score (CLASI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum levels of hydroxycloroquine - HCQ reduced</measure>
    <time_frame>6 months, 12 months and 24 months</time_frame>
    <description>Disease flare evaluated by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum levels of hydroxycloroquine - HCQ high</measure>
    <time_frame>3 months</time_frame>
    <description>Disease flare evaluated by Systemic Lupus Erythematosus Disease Activity Index</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">296</enrollment>
  <condition>Systemic Lupus Erythematosus (SLE)</condition>
  <condition>Juvenile SLE</condition>
  <condition>Cutaneous Lupus</condition>
  <arm_group>
    <arm_group_label>SLE/cutaneous lupus with thalidomide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This subproject includes only one arm of lupus patients with active and refractory cutaneous disease and eligible for Thalidomide 100mg/day for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive SLE with standard dose of HCQ</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This subproject includes 2 arms of lupus patients with inactive disease: one group will be maintained on standard dose of Hydroxychloroquine (400mg/day) and in the other, the dose will be reduced to 400mg 3 times a week for two years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive SLE with reduced dose of HCQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This subproject includes 2 arms of lupus patients with inactive disease: one group will be maintained on standard dose of Hydroxychloroquine (400mg/day) for two years and in the other, the dose will be reduced to 400mg 3 times a week (Hydroxychloroquine reduced) for two years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active SLE with initial high dose of HCQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This subproject includes 2 arms of lupus patients with active disease: one group will be started on standard dose of Hydroxychloroquine (400mg/day) for two years and in the other, the dose will be started at high dose 800mg/day (Hydroxychloroquine high) for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active SLE with standard dose of HCQ</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This subproject includes 2 arms of lupus patients with active disease: one group will be started on standard dose of Hydroxychloroquine (400mg/day) for three months and in the other, the dose will be started at high dose 800mg/day (Hydroxychloroquine high) for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide 100mg/day</description>
    <arm_group_label>SLE/cutaneous lupus with thalidomide</arm_group_label>
    <other_name>Thalidomide 100 MG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine reduced</intervention_name>
    <description>Hydroxychloroquine 400mg three times a week</description>
    <arm_group_label>Inactive SLE with reduced dose of HCQ</arm_group_label>
    <other_name>HCQ reduced</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine high</intervention_name>
    <description>Hydroxychloroquine 800mg/day for three months</description>
    <arm_group_label>Active SLE with initial high dose of HCQ</arm_group_label>
    <other_name>HCQ high</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Thalidomide subproject:

        Inclusion Criteria:

          -  SLE diagnosis according to 1997 ACR criteria

          -  Active and refractory cutaneous lupus lesions

          -  Male gender (using contraceptive barrier method) or confirmed infertility for female
             gender

          -  Normal electroneuromyography at study entry

        Exclusion Criteria:

          -  Alcoholism

          -  History of peripheral neuropathy

          -  Previous history of thrombophilia or positive antiphospholipid antibodies

          -  Renal and/or central nervous system and/or hematological activity

        HCQ reduced subproject:

        Inclusion Criteria:

          -  SLE diagnosis according to 1997 ACR criteria

          -  Use of hydroxychloroquine (5 to 6.5mg/kg/day) for ≥5 years

          -  SLEDAI-2K &lt;4

        Exclusion Criteria:

          -  Alcoholism

          -  Renal dialysis

          -  Concomitant infectious process

          -  Acute and chronic liver diseases

          -  Concomitant use of some drugs that interact with HCQ (cimetidine, antacids, digoxin,
             aminoglycosides, penicillamine, neostigmine, pyridostigmine)

          -  Signs of Retinopathy

        HCQ high subproject:

        Inclusion Criteria:

          -  SLE diagnosis according to 1997 ACR criteria

          -  No use of hydroxychloroquine for ≥ 6 months

          -  LES/LESJ in activity (SLEDAI≥6)

        Exclusion Criteria:

          -  Alcoholism

          -  Renal dialysis

          -  Concomitant infectious process

          -  Acute and chronic liver diseases

          -  Concomitant use of some drugs that interact with HCQ (cimetidine, antacids, digoxin,
             aminoglycosides, penicillamine, neostigmine, pyridostigmine)

          -  Signs of Retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eloisa Bonfa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eloisa Bonfa, MD, PhD</last_name>
    <phone>55 11 30617490</phone>
    <email>eloisa.bonfa@hc.fm.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clovis Silva, MD, PhD</last_name>
    <phone>55 11 26618563</phone>
    <email>clovisaasilva@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra G Pasoto, M.D., PhD.</last_name>
      <phone>30617490</phone>
      <email>sandra.pasoto@hc.fm.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Nadia E Aikawa, M.D., PhD.</last_name>
      <phone>30617490</phone>
      <email>nadia.aikawa@hc.fm.usp.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, Kantor J, Kim E, Militello G, McGinnis K, Richardson S, Treat J, Vittorio C, Van Voorhees A, Werth VP. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005 Nov;125(5):889-94.</citation>
    <PMID>16297185</PMID>
  </reference>
  <reference>
    <citation>Bai N, Cui XY, Wang J, Sun CG, Mei HK, Liang BB, Cai Y, Song XJ, Gu JK, Wang R. Determination of thalidomide concentration in human plasma by liquid chromatography-tandem mass spectrometry. Exp Ther Med. 2013 Feb;5(2):626-630. Epub 2012 Nov 30.</citation>
    <PMID>23404219</PMID>
  </reference>
  <reference>
    <citation>Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol. 1991 Aug;23(8):292-6. Review.</citation>
    <PMID>1952638</PMID>
  </reference>
  <reference>
    <citation>Briani C, Zara G, Rondinone R, Della Libera S, Ermani M, Ruggero S, Ghirardello A, Zampieri S, Doria A. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology. 2004 Jun 22;62(12):2288-90.</citation>
    <PMID>15210897</PMID>
  </reference>
  <reference>
    <citation>Coelho A, Souto MI, Cardoso CR, Salgado DR, Schmal TR, Waddington Cruz M, de Souza Papi JA. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus. 2005;14(6):434-9.</citation>
    <PMID>16038106</PMID>
  </reference>
  <reference>
    <citation>Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, Francès C, Wechsler B, Huong du LT, Ghillani P, Musset L, Lechat P, Piette JC. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006 Oct;54(10):3284-90.</citation>
    <PMID>17009263</PMID>
  </reference>
  <reference>
    <citation>Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, Le Guern V, Leroux G, Marra D, Morel N, Piette JC. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013 Jun;27(3):329-40. doi: 10.1016/j.berh.2013.07.001. Review.</citation>
    <PMID>24238690</PMID>
  </reference>
  <reference>
    <citation>Costedoat-Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot-Imbert G. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med. 2014 Jun;43(6 Pt 2):e167-80. doi: 10.1016/j.lpm.2014.03.007. Epub 2014 May 19. Review.</citation>
    <PMID>24855048</PMID>
  </reference>
  <reference>
    <citation>Cuadrado MJ, Karim Y, Sanna G, Smith E, Khamashta MA, Hughes GR. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005 Mar;118(3):246-50.</citation>
    <PMID>15745722</PMID>
  </reference>
  <reference>
    <citation>Francès C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, Bessis D, Chevrant-Breton J, Cordel N, Lipsker D, Costedoat-Chalumeau N. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. 2012 Apr;148(4):479-84. doi: 10.1001/archdermatol.2011.2558.</citation>
    <PMID>22508872</PMID>
  </reference>
  <reference>
    <citation>Giannini F, Volpi N, Rossi S, Passero S, Fimiani M, Cerase A. Thalidomide-induced neuropathy: a ganglionopathy? Neurology. 2003 Mar 11;60(5):877-8.</citation>
    <PMID>12629253</PMID>
  </reference>
  <reference>
    <citation>Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91.</citation>
    <PMID>11838846</PMID>
  </reference>
  <reference>
    <citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725.</citation>
    <PMID>9324032</PMID>
  </reference>
  <reference>
    <citation>Jallouli M, Galicier L, Zahr N, Aumaître O, Francès C, Le Guern V, Lioté F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Le Thi Huong D, Asli B, Kahn JE, Pourrat J, Sailler L, Ackermann F, Papo T, Sacré K, Fain O, Stirnemann J, Cacoub P, Leroux G, Cohen-Bittan J, Sellam J, Mariette X, Blanchet B, Hulot JS, Amoura Z, Piette JC, Costedoat-Chalumeau N; Plaquenil Lupus Systemic Study Group. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015 May;67(8):2176-84. doi: 10.1002/art.39194.</citation>
    <PMID>25989906</PMID>
  </reference>
  <reference>
    <citation>Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, Macher E. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. 1983 Apr;108(4):461-6.</citation>
    <PMID>6838771</PMID>
  </reference>
  <reference>
    <citation>Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol. 2000 Mar;39(3):218-22.</citation>
    <PMID>10759967</PMID>
  </reference>
  <reference>
    <citation>Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011 Jan;129(1):30-9. doi: 10.1001/archophthalmol.2010.321.</citation>
    <PMID>21220626</PMID>
  </reference>
  <reference>
    <citation>Morita S, Takahashi T, Yoshida Y, Yokota N. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus. Ther Drug Monit. 2016 Apr;38(2):259-67. doi: 10.1097/FTD.0000000000000261.</citation>
    <PMID>26587870</PMID>
  </reference>
  <reference>
    <citation>Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senécal JL, Cividino A, Danoff D, Osterland CK, Yeadon C, Smith CD. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7(2):80-5.</citation>
    <PMID>9541091</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

